Geron (NASDAQ:GERN) versus Shattuck Labs (NASDAQ:STTK) Critical Contrast

Shattuck Labs (NASDAQ:STTK) and Geron (NASDAQ:GERN) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, valuation, profitability, institutional ownership and earnings.

Analyst Recommendations

This is a breakdown of current ratings for Shattuck Labs and Geron, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Shattuck Labs	1	0	10	0	2.82
Geron	1	2	2	0	2.20

Shattuck Labs presently has a consensus target price of $12.62, indicating a potential upside of 74.62%. Geron has a consensus target price of $4.00, indicating a potential upside of 157.57%. Given Geron’s higher probable upside, analysts plainly believe Geron is more favorable than Shattuck Labs.

Profitability

This table compares Shattuck Labs and Geron’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Shattuck Labs	N/A	-60.73%	-55.75%
Geron	-34.17%	-24.48%	-10.30%

Valuation & Earnings

This table compares Shattuck Labs and Geron”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Shattuck Labs	$1.00 million	554.40	-$48.81 million	($0.63)	-11.48
Geron	$183.88 million	5.43	-$83.50 million	($0.11)	-14.12

Shattuck Labs has higher earnings, but lower revenue than Geron. Geron is trading at a lower price-to-earnings ratio than Shattuck Labs, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

58.7% of Shattuck Labs shares are held by institutional investors. Comparatively, 73.7% of Geron shares are held by institutional investors. 8.8% of Shattuck Labs shares are held by company insiders. Comparatively, 1.7% of Geron shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Volatility & Risk

Shattuck Labs has a beta of 1.08, indicating that its share price is 8% more volatile than the S&P 500. Comparatively, Geron has a beta of 0.61, indicating that its share price is 39% less volatile than the S&P 500.

Summary

Shattuck Labs beats Geron on 8 of the 14 factors compared between the two stocks.

About Shattuck Labs

Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas.

About Geron

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.